“精准医疗”时代从乳腺癌分子分型探讨抗体-药物偶联物的临床价值及最新研究进展

王雪儿; 王永胜

doi:10.19401/j.cnki.1007-3639.2023.12.002

您当前的位置：

首页 >

文章列表页 >

“精准医疗”时代从乳腺癌分子分型探讨抗体-药物偶联物的临床价值及最新研究进展

综述 | 更新时间：2025-12-31

- “精准医疗”时代从乳腺癌分子分型探讨抗体-药物偶联物的临床价值及最新研究进展
- The research advances and the clinical value of antibody-drug conjugate from molecular subtyping of breast cancer in the era of "precision medicine"
- 中国癌症杂志 2023年33卷第12期页码：1073-1082
- 作者机构：
  
  1. 天津医科大学肿瘤医院肿瘤科，国家肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060
  2. 山东省肿瘤防治研究院（山东省肿瘤医院）乳腺病中心，山东第一医科大学（山东省医学科学院），山东济南 250117
- 作者简介：
  
  [ "王雪儿（ORCID: 0009-0004-0103-0655），博士。" ]
  王永胜（ORCID: 0000-0001-6252-684X），主任医师，山东省肿瘤医院大外科主任兼乳腺病中心主任.
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.12.002
  中图分类号： R737.9
- 收稿：2023-06-25，
  
  修回：2023-10-20，
  
  纸质出版：2023-12-30
- 稿件说明：
移动端阅览
王雪儿, 王永胜. “精准医疗”时代从乳腺癌分子分型探讨抗体-药物偶联物的临床价值及最新研究进展[J]. 中国癌症杂志, 2023,33(12):1073-1082.

Xueer WANG, Yongsheng WANG. The research advances and the clinical value of antibody-drug conjugate from molecular subtyping of breast cancer in the era of "precision medicine"[J]. China Oncology, 2023, 33(12): 1073-1082.
王雪儿, 王永胜. “精准医疗”时代从乳腺癌分子分型探讨抗体-药物偶联物的临床价值及最新研究进展[J]. 中国癌症杂志, 2023,33(12):1073-1082. DOI： 10.19401/j.cnki.1007-3639.2023.12.002.

Xueer WANG, Yongsheng WANG. The research advances and the clinical value of antibody-drug conjugate from molecular subtyping of breast cancer in the era of "precision medicine"[J]. China Oncology, 2023, 33(12): 1073-1082. DOI： 10.19401/j.cnki.1007-3639.2023.12.002.

摘要

乳腺癌的发病率目前已位居女性恶性肿瘤之首。乳腺癌具有高度异质性，可分为luminal A、luminal B、人类表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）过表达及三阴性型4种分子分型。然而既往的分子分型方法导致处于HER2低表达状态患者的治疗选择十分有限。近年来，随着抗体-药物偶联物（antibody-drug conjugate，ADC）的飞速发展，使HER2低表达乳腺癌患者获得了新的治疗选择，并促进了当前国内外指南中对HER2表达状态判定标准的更新——基于免疫组化（immuno

histochemistry，IHC）和原位杂交（

in situ

hybridization，ISH）检测技术，将HER2的表达分为HER2阳性（IHC 3+或IHC 2+/ISH+）、HER2低表达（IHC 1+或IHC 2+/ISH-）以及HER2阴性（IHC 0）3种情况。ADC是一种由连接子将单克隆抗体与细胞毒性物质偶联而成的免疫偶联物。在乳腺癌领域，多项大型临床试验已经证明了以HER2为靶点的ADC恩美曲妥珠单抗（T-DM1）、德曲妥珠单抗（T-DXd）以及以滋养层细胞表面抗原2（trophoblast cell surface antigen 2，TROP2）为靶点的ADC戈沙妥珠单抗在不同分子分型乳腺癌患者中的临床获益。随着DESTINY-Breast03等Ⅲ期临床试验发现T-DXd在晚期HER2阳性乳腺癌患者中的临床疗效优于T-DM1（完全缓解率约为T-DM1的2倍，中位无进展生存期约为T-DM1的4倍），T-DXd现今已经替代T-DM1成为HER2阳性乳腺癌二线治疗唯一推荐的药物，也是脑转移局部治疗后二线治疗的选择。Ⅲ期临床试验DESTINY-Breast04证实T-DXd同样可使HER2低表达的乳腺癌患者获益，这进一步改变了晚期乳腺癌的治疗格局，并支持重新定义HER2阴性乳腺癌分子亚型的必要。Ⅲ期临床试验ASCENT证实戈沙妥珠单抗可显著改善三阴性乳腺癌（triple-negative breast cancer，TNBC）患者的生存情况及生活质量，且Ⅱ期临床试验NeoSTAR发现该药在TNBC新辅助治疗中也可能具有良好的抗肿瘤作用。基于循证医学证据，目前T-DM1、T-DXd和戈沙妥珠单抗均已在国外和中国陆续获批上市。其他如HER3-DXd、Dato-DXd及中国研发的纬迪西妥单抗（RC48）等ADC药物也正在乳腺癌等肿瘤中广泛地开展临床研究。此外，尚有多种其他分子靶点的ADC仍正在积极地研发中。本文旨在从不同分子分型乳腺癌患者的ADC药物治疗出发，介绍最新的相关研究进展并探讨ADC在乳腺癌中的临床应用价值。

Abstract

The incidence of breast cancer currently ranks first among malignant tumors in women. Breast cancer exhibits high heterogeneity and can be classified into four molecular subtypes: luminal A

luminal B

human epidermal growth factor receptor 2 (HER2) overexpression and triple-negative. However

previous molecular subtype classifications have limited treatment options for patients with HER2 low expression. In recent years

with the rapid development of antibody-drug conjugates (ADCs)

new treatment options have emerged for breast cancer patients with HER2 low expression. This has also led to updates in the criteria for determining HER2 expression status in both domestic and international guidelines

based on immunohistochemistry (IHC) and

in situ

hybridization (ISH) testing

categorizing HER2 expression as HER2-positive (IHC 3+ or IHC 2+/ISH+)

HER2 low expression (IHC 1+ or IHC 2+/ISH-)

and HER2-negative (IHC 0). ADCs are immunotherapeutics composed of a linker that conjugates a monoclonal antibody with a cytotoxic payload. In the

field of breast cancer

several large clinical trials have demonstrated clinical benefits of ADCs targeting HER2

such as trastuzumab emtansine (T-DM1)

trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan targeting trophoblast cell surface antigen 2 (TROP2)

in various molecular subtypes of breast cancer. With the phase Ⅲ DESTINY-Breast03 trial and others

T-DXd has been found to have superior efficacy compared to T-DM1 in advanced HER2-positive breast cancer patients (approximately two times higher complete response rate

and four times longer median progression-free survival). T-DXd has now replaced T-DM1 as the recommended second-line therapy for HER2-positive breast cancer and as a second-line treatment option after local treatment for brain metastasis. The phase Ⅲ DESTINY-Breast04 trial confirmed that breast cancer patients with HER2 low expression can also benefit from T-DXd

further reshaping the treatment landscape for advanced breast cancer and supporting the need to redefine molecular subtypes of HER2-negative breast cancer. The phase Ⅲ ASCENT trial demonstrated that sacituzumab govitecan significantly improved survival and quality of life in triple-negative breast cancer (TNBC) patients

and the phase Ⅱ NeoSTAR study suggested its potential as neoadjuvant therapy in TNBC. Based on evidence

T-DM1

T-DXd and sacituzumab govitecan have been approved for marketing in both foreign and Chinese markets. Other ADC drugs

such as HER3-DXd

Dato-DXd and China-developed RC48

are also undergoing extensive clinical trials in the field of breast cancer and other tumors. Furthermore

there are several other ADCs targeting different molecular targets in active development. This article aimed to review the new advances related to ADCs therapy for breast cancer patients with different molecular subtypes and discuss the clinical application value of ADCs in breast cancer.

关键词

Keywords

references

World Health Organization . Global cancer observatory. Estimated number of new cases in 2020, World, both sexes, all ages [EB/OL ] . 2020 [ 2022 - 11 - 10 ] . https://gco.iarc.fr/today/home https://gco.iarc.fr/today/home https://gco.iarc.fr/today/home .

周昌明 , 王泽洲 , 郑莹 . 2023年美国癌症数据解读及对中国癌症防治的启示 [J ] . 中国癌症杂志 , 2023 , 33 ( 2 ): 117 - 125 . DOI: 10.19401/j.cnki.1007-3639.2023.02.004 http://doi.org/10.19401/j.cnki.1007-3639.2023.02.004

ZHOU C M , WANG Z Z , ZHENG Y . Interpretation of US cancer statistics 2023 and its implications for cancer prevention and treatment in China [J ] . China Oncol , 2023 , 33 ( 2 ): 117 - 125 .

TARANTINO P , HAMILTON E , TOLANEY S M , et al . HER2-low breast cancer: pathological and clinical landscape [J ] . J Clin Oncol , 2020 , 38 ( 17 ): 1951 - 1962 . DOI: 10.1200/JCO.19.02488 http://doi.org/10.1200/JCO.19.02488

WOLFF A C , HAMMOND M E H , ALLISON K H , et al . Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update [J ] . J Clin Oncol , 2018 , 36 ( 20 ): 2105 - 2122 . DOI: 10.1200/JCO.2018.77.8738 http://doi.org/10.1200/JCO.2018.77.8738

T-DXd: New standard for HER2-low breast cancer [J ] . Cancer Discov , 2022 , 12 ( 8 ): 1828 . DOI: 10.1158/2159-8290.CD-NB2022-0043 http://doi.org/10.1158/2159-8290.CD-NB2022-0043

邬茜 , 辛灵 , 刘倩 , 等 . HER2低表达乳腺癌及抗体偶联药物诊治进展 [J ] . 中华临床医师杂志(电子版) , 2021 , 15 ( 10 ): 735 - 739 .

WU Q , XIN L , LIU Q , et al . Advances in diagnosis and treatment of HER2-low breast cancer and antibody drug conjugates [J ] . Chin J Clin Electron Ed , 2021 , 15 ( 10 ): 735 - 739 .

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

JOUBERT N , BECK A , DUMONTET C , et al . Antibody-drug conjugates: the last decade [J ] . Pharmaceuticals (Basel) , 2020 , 13 ( 9 ): 245 . DOI: 10.3390/ph13090245 http://doi.org/10.3390/ph13090245 https://www.mdpi.com/1424-8247/13/9/245 https://www.mdpi.com/1424-8247/13/9/245

SCHLAM I , MOGES R , MORGANTI S , et al . Next-generation antibody-drug conjugates for breast cancer: moving beyond HER2 and TROP2 [J ] . Crit Rev Oncol Hematol , 2023 , 190 : 104090 . DOI: 10.1016/j.critrevonc.2023.104090 http://doi.org/10.1016/j.critrevonc.2023.104090 https://linkinghub.elsevier.com/retrieve/pii/S1040842823001786 https://linkinghub.elsevier.com/retrieve/pii/S1040842823001786

WANG J Y , LIU Y J , ZHANG Q Y , et al . RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 1022 . DOI: 10.1200/JCO.2021.39.15_suppl.1022 http://doi.org/10.1200/JCO.2021.39.15_suppl.1022 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.1022 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.1022

BANYS-PALUCHOWSKI M , KRAWCZYK N , STICKELER E , et al . New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023 [J ] . Curr Opin Obstet Gynecol , 2023 , 35 ( 1 ): 54 - 61 . DOI: 10.1097/GCO.0000000000000830 http://doi.org/10.1097/GCO.0000000000000830 https://journals.lww.com/10.1097/GCO.0000000000000830 https://journals.lww.com/10.1097/GCO.0000000000000830

VON ARX C , DE PLACIDO P , CALTAVITURO A , et al . The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer [J ] . Cancer Treat Rev , 2023 , 113 : 102500 . DOI: 10.1016/j.ctrv.2022.102500 http://doi.org/10.1016/j.ctrv.2022.102500 https://linkinghub.elsevier.com/retrieve/pii/S0305737222001761 https://linkinghub.elsevier.com/retrieve/pii/S0305737222001761

MODI S N , JACOT W , YAMASHITA T , et al . Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [J ] . N Engl J Med , 2022 , 387 ( 1 ): 9 - 20 . DOI: 10.1056/NEJMoa2203690 http://doi.org/10.1056/NEJMoa2203690 http://www.nejm.org/doi/10.1056/NEJMoa2203690 http://www.nejm.org/doi/10.1056/NEJMoa2203690

VERMA S , MILES D , GIANNI L , et al . Trastuzumab emtansine for HER2-positive advanced breast cancer [J ] . N Engl J Med , 2012 , 367 ( 19 ): 1783 - 1791 . DOI: 10.1056/NEJMoa1209124 http://doi.org/10.1056/NEJMoa1209124 http://www.nejm.org/doi/10.1056/NEJMoa1209124 http://www.nejm.org/doi/10.1056/NEJMoa1209124

CORTÉS J , KIM S B , CHUNG W P , et al . Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer [J ] . N Engl J Med , 2022 , 386 ( 12 ): 1143 - 1154 . DOI: 10.1056/NEJMoa2115022 http://doi.org/10.1056/NEJMoa2115022 http://www.nejm.org/doi/10.1056/NEJMoa2115022 http://www.nejm.org/doi/10.1056/NEJMoa2115022

HURVITZ S A , HEGG R , CHUNG W P , et al . Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [J ] . Lancet , 2023 , 401 ( 10371 ): 105 - 117 . DOI: 10.1016/S0140-6736(22)02420-5 http://doi.org/10.1016/S0140-6736(22)02420-5 https://linkinghub.elsevier.com/retrieve/pii/S0140673622024205 https://linkinghub.elsevier.com/retrieve/pii/S0140673622024205

KROP I E , KIM S B , GONZÁLEZ-MARTÍN A , et al . Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial [J ] . Lancet Oncol , 2014 , 15 ( 7 ): 689 - 699 . DOI: 10.1016/S1470-2045(14)70178-0 http://doi.org/10.1016/S1470-2045(14)70178-0 https://linkinghub.elsevier.com/retrieve/pii/S1470204514701780 https://linkinghub.elsevier.com/retrieve/pii/S1470204514701780

EMENS L A , ESTEVA F J , BERESFORD M , et al . Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial [J ] . Lancet Oncol , 2020 , 21 ( 10 ): 1283 - 1295 . DOI: S1470-2045(20)30465-4 http://doi.org/S1470-2045(20)30465-4

HURVITZ S A , DIRIX L , KOCSIS J , et al . Phase Ⅱ randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [J ] . J Clin Oncol , 2013 , 31 ( 9 ): 1157 - 1163 . DOI: 10.1200/JCO.2012.44.9694 http://doi.org/10.1200/JCO.2012.44.9694 https://ascopubs.org/doi/10.1200/JCO.2012.44.9694 https://ascopubs.org/doi/10.1200/JCO.2012.44.9694

National Comprehensive Cancer Network . Clinical practice guidelines in oncology: breast cancer (version 4.2023) 2023 [EB/OL ] . https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf .

RAMAKRISHNA N , ANDERS C K , LIN N U , et al . Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update [J ] . J Clin Oncol , 2022 , 40 ( 23 ): 2636 - 2655 .

GENNARI A , ANDRÉ F , BARRIOS C H , et al . ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer [J ] . Ann Oncol , 2021 , 32 ( 12 ): 1475 - 1495 . DOI: 10.1016/j.annonc.2021.09.019 http://doi.org/10.1016/j.annonc.2021.09.019

BASELGA J , CORTÉS J , KIM S B , et al . Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer [J ] . N Engl J Med , 2012 , 366 ( 2 ): 109 - 119 . DOI: 10.1056/NEJMoa1113216 http://doi.org/10.1056/NEJMoa1113216 http://www.nejm.org/doi/abs/10.1056/NEJMoa1113216 http://www.nejm.org/doi/abs/10.1056/NEJMoa1113216

PEREZ E A , BARRIOS C , EIERMANN W , et al . Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase Ⅲ MARIANNE study [J ] . J Clin Oncol , 2017 , 35 ( 2 ): 141 - 148 .

HURVITZ S , HEGG R , CHUNG W P , et al . Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated survival results of the randomized, phase 3 study DESTINY-Breast03 [J ] . Cancer Res , 2023 , 83 ( 5_Supplement ): GS2 - 2 .

SAURA C , OLIVEIRA M , FENG Y H , et al . Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase Ⅲ NALA trial [J ] . J Clin Oncol , 2020 , 38 ( 27 ): 3138 - 3149 . DOI: 10.1200/JCO.20.00147 http://doi.org/10.1200/JCO.20.00147 https://ascopubs.org/doi/10.1200/JCO.20.00147 https://ascopubs.org/doi/10.1200/JCO.20.00147

MURTHY R K , LOI S , OKINES A , et al . Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer [J ] . N Engl J Med , 2020 , 382 ( 7 ): 597 - 609 . DOI: 10.1056/NEJMoa1914609 http://doi.org/10.1056/NEJMoa1914609 http://www.nejm.org/doi/10.1056/NEJMoa1914609 http://www.nejm.org/doi/10.1056/NEJMoa1914609

JACOBSON A . Trastuzumab deruxtecan improves progression-free survival and intracranial response in patients with HER2-positive metastatic breast cancer and brain metastases [J ] . Oncologist , 2022 , 27 ( Suppl 1 ): S3 -S4. DOI: 10.1093/oncolo/oyac009 http://doi.org/10.1093/oncolo/oyac009 https://academic.oup.com/oncolo/article/27/Supplement_1/S3/6554902 https://academic.oup.com/oncolo/article/27/Supplement_1/S3/6554902

BARTSCH R , BERGHOFF A S , FURTNER J , et al . Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial [J ] . Nat Med , 2022 , 28 ( 9 ): 1840 - 1847 . DOI: 10.1038/s41591-022-01935-8 http://doi.org/10.1038/s41591-022-01935-8

PÉREZ-GARCÍA J M , VAZ BATISTA M , CORTEZ P , et al . Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial [J ] . Neuro Oncol , 2023 , 25 ( 1 ): 157 - 166 . DOI: 10.1093/neuonc/noac144 http://doi.org/10.1093/neuonc/noac144 https://academic.oup.com/neuro-oncology/article/25/1/157/6593857 https://academic.oup.com/neuro-oncology/article/25/1/157/6593857

YAMANAKA T , NIIKURA N , NOMURA H , et al . Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: a multicenter retrospective study (ROSET-BM study) [J ] . Cancer Res , 2023 , 83 ( 5_Supplement ): PD7 - 1 .

WYNN C S , TANG S C . Anti-HER2 therapy in metastatic breast cancer: many choices and future directions [J ] . Cancer Metastasis Rev , 2022 , 41 ( 1 ): 193 - 209 . DOI: 10.1007/s10555-022-10021-x http://doi.org/10.1007/s10555-022-10021-x

SCHETTINI F , CHIC N , BRASÓ-MARISTANY F , et al . Clinical, pathological, and PAM 50 gene expression features of HER2-low breast cancer [J ] . NPJ Breast Cancer , 2021 , 7 ( 1 ): 1 . DOI: 10.1038/s41523-020-00208-2 http://doi.org/10.1038/s41523-020-00208-2

MIGLIETTA F , GRIGUOLO G , BOTTOSSO M , et al . Evolution of HER2-low expression from primary to recurrent breast cancer [J ] . NPJ Breast Cancer , 2021 , 7 ( 1 ): 137 . DOI: 10.1038/s41523-021-00343-4 http://doi.org/10.1038/s41523-021-00343-4

PEIFFER D S , ZHAO F Y , CHEN N , et al . Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the national cancer database [J ] . JAMA Oncol , 2023 , 9 ( 4 ): 500 - 510 . DOI: 10.1001/jamaoncol.2022.7476 http://doi.org/10.1001/jamaoncol.2022.7476 https://jamanetwork.com/journals/jamaoncology/fullarticle/2801799 https://jamanetwork.com/journals/jamaoncology/fullarticle/2801799

HARBECK N , MODI S N , JACOT W , et al . Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: subgroup analyses from DESTINY-Breast04 [J ] . Cancer Res , 2023 , 83 ( 5_Supplement ): P1 - 11 .

NARAYAN P , DILAWARI A , OSGOOD C , et al . US food and drug administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer [J ] . J Clin Oncol , 2023 , 41 ( 11 ): 2108 - 2116 . DOI: 10.1200/JCO.22.02447 http://doi.org/10.1200/JCO.22.02447 https://ascopubs.org/doi/10.1200/JCO.22.02447 https://ascopubs.org/doi/10.1200/JCO.22.02447

RUGO H S , BARDIA A , MARMÉ F , et al . Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer [J ] . J Clin Oncol , 2022 , 40 ( 29 ): 3365 - 3376 . DOI: 10.1200/JCO.22.01002 http://doi.org/10.1200/JCO.22.01002 https://ascopubs.org/doi/10.1200/JCO.22.01002 https://ascopubs.org/doi/10.1200/JCO.22.01002

KUMARI L , MISHRA L , PATEL P , et al . Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer [J ] . J Drug Target , 2023 : 1 - 19 .

JEON Y , JO U , HONG J , et al . Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer [J ] . BMC Cancer , 2022 , 22 ( 1 ): 1014 . DOI: 10.1186/s12885-022-10076-7 http://doi.org/10.1186/s12885-022-10076-7

BARDIA A , HURVITZ S A , TOLANEY S M , et al . Sacituzumab govitecan in metastatic triple-negative breast cancer [J ] . N Engl J Med , 2021 , 384 ( 16 ): 1529 - 1541 . DOI: 10.1056/NEJMoa2028485 http://doi.org/10.1056/NEJMoa2028485 http://www.nejm.org/doi/10.1056/NEJMoa2028485 http://www.nejm.org/doi/10.1056/NEJMoa2028485

LOIBL S , LOIRAT D , TOLANEY S M , et al . Health-related quality of life in the phase Ⅲ ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer [J ] . Eur J Cancer , 2023 , 178 : 23 - 33 . DOI: 10.1016/j.ejca.2022.10.003 http://doi.org/10.1016/j.ejca.2022.10.003 https://linkinghub.elsevier.com/retrieve/pii/S0959804922007997 https://linkinghub.elsevier.com/retrieve/pii/S0959804922007997

SPRING L , TOLANEY S , DESAI N , et al . Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial [J ] . J Clin Oncol , 2022 , 40 : 512 - 512 .

JABBARZADEH KABOLI P , SHABANI S , SHARMA S , et al . Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates [J ] . Am J Cancer Res , 2022 , 12 ( 4 ): 1671 - 1685 .

BARDIA A , KROP I , MERIC-BERNSTAM F , et al . Datopotamab deruxtecan (dato-DXd) in advanced triple-negative breast cancer (TNBC): updated results from the phase 1 TROPION-PanTumor01 study [J ] . Cancer Res , 2023 , 83 ( 5_Supplement ): P6 - 10 .

ANDRÉ F , HEE PARK Y , KIM S B , et al . Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial [J ] . Lancet , 2023 , 401 ( 10390 ): 1773 - 1785 . DOI: 10.1016/S0140-6736(23)00725-0 http://doi.org/10.1016/S0140-6736(23)00725-0 https://linkinghub.elsevier.com/retrieve/pii/S0140673623007250 https://linkinghub.elsevier.com/retrieve/pii/S0140673623007250

DIECI M V , MIGLIETTA F , GRIGUOLO G , et al . Biomarkers for HER2-positive metastatic breast cancer: beyond hormone receptors [J ] . Cancer Treat Rev , 2020 , 88 : 102064 . DOI: 10.1016/j.ctrv.2020.102064 http://doi.org/10.1016/j.ctrv.2020.102064 https://linkinghub.elsevier.com/retrieve/pii/S030573722030102X https://linkinghub.elsevier.com/retrieve/pii/S030573722030102X

KOYAMA K , ISHIKAWA H , ABE M , et al . Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression [J ] . PLoS One , 2022 , 17 ( 5 ): e0267027 . DOI: 10.1371/journal.pone.0267027 http://doi.org/10.1371/journal.pone.0267027 https://dx.plos.org/10.1371/journal.pone.0267027 https://dx.plos.org/10.1371/journal.pone.0267027

ALVES F R , GIL L , VASCONCELOS DE MATOS L , et al . Impact of human epidermal growth factor receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer [J ] . Cureus , 2022 , 14 ( 2 ): e22330 .

TARANTINO P , JIN Q C , TAYOB N , et al . Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer [J ] . JAMA Oncol , 2022 , 8 ( 8 ): 1177 - 1183 . DOI: 10.1001/jamaoncol.2022.2286 http://doi.org/10.1001/jamaoncol.2022.2286

CHERIFI F , DA SILVA A , JOHNSON A , et al . HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer [J ] . BMC Cancer , 2022 , 22 ( 1 ): 1081 . DOI: 10.1186/s12885-022-10163-9 http://doi.org/10.1186/s12885-022-10163-9

WOLFF A C , SOMERFIELD M R , DOWSETT M , et al . Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update [J ] . J Clin Oncol , 2023 , 41 ( 22 ): 3867 - 3872 . DOI: 10.1200/JCO.22.02864 http://doi.org/10.1200/JCO.22.02864 https://ascopubs.org/doi/10.1200/JCO.22.02864 https://ascopubs.org/doi/10.1200/JCO.22.02864

浏览量

3087

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中国抗癌协会乳腺癌诊治指南与规范（2026年版）

着丝粒蛋白A驱动的染色体不稳定性与乳腺癌相关性研究的进展及展望：机制、预后及临床靶向治疗应用

中国年轻女性乳腺癌发病、死亡近30年的变迁情况及趋势研究

miR-193a-3p通过靶向TRIM14对乳腺癌干细胞迁移和侵袭的影响

乳腺癌新辅助治疗后的腋窝管理及前哨淋巴结诊治的优化